Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial

Figure 4 Analyzed by fecal calprotectin and simple clinical colitis activity index for all patients at risk. A: Time to severe relapse (in days) measured by fecal calprotectin for all patients at risk (n = 83); B: The corresponding (days) to remission (n = 27); C: Time in days to a severe relapse measured by simple clinical colitis activity index for all patients with ulcerative colitis at risk (n = 70); D: The corresponding time (days) to remission (n = 16). The two electronic health screening procedures (every third month and on demand) are represented by blue and red lines, respectively.